Skip to main content
. Author manuscript; available in PMC: 2021 Feb 19.
Published in final edited form as: Biol Psychiatry. 2018 Mar 6;84(6):433–442. doi: 10.1016/j.biopsych.2018.02.1171

Figure 2.

Figure 2.

Standardized difference in translocator protein levels (estimated using total distribution volume [VT]) between patients with psychosis and healthy control subjects. The posterior distribution for each study-specific difference in VT (ΔVT) estimate (random slopes) from the linear mixed model is presented. The black circle denotes the posterior mean, and the thick line denotes the 95% credible interval; these are also presented in text next to the plots. The cross denotes the patient–control mean difference in raw data (together with its 95% credible interval) without performing linear mixed-effects modeling. Hence, the difference between the dot and the cross displays the model shrinkage toward the mean. The overall ΔVT estimate suggests that patients with schizophrenia or first-episode psychosis have lower levels of translocator protein compared with healthy control subjects. Included studies: Bloomfield et al. (22); Collste et al. (23); Coughlin et al. (24); Hafizi et al. (25); Kenk et al. (26).